Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 16/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13368583 | 0.89 | MAP4K1 (0.44) | MAP4K1CYP3A4ABL1PIK3C3PDE11A | |
| SCHEMBL3567049 | 0.79 | MAP4K1 (0.41) | MAP4K1CYP3A4ABL1ALOX5AP | |
| SCHEMBL3560214 | 0.79 | GSK3B (0.35) | PDE11A | |
| SCHEMBL3561393 | 0.77 | MAP4K1 (0.67) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL3488673 | 0.73 | MAP4K1 (0.56) | MAP4K1CYP3A4ABL1ALOX5AP | |
| SCHEMBL3489573 | 0.72 | MAP4K1 (0.43) | MAP4K1CYP3A4ABL1PIK3C3ALOX5AP | |
| SCHEMBL3489336 | 0.71 | MAP4K1 (0.43) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL3489045 | 0.66 | MAP4K1 (0.51) | MAP4K1CYP3A4ABL1ALOX5AP | |
| SCHEMBL3491882 | 0.65 | MAP4K1 (0.50) | MAP4K1CYP3A4ABL1PIK3C3ALOX5AP | |
| SCHEMBL3566219 | 0.65 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | MAP4K2, PDXK, MAP4K1 | MAP4K1 3/4885CYP3A4 3552/4885ABL1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.